Structure-Activity Analysis of the Interaction of Curacin A, the Potent Colchicine Site Antimitotic Agent, with Tubulin and Effects of Analogs on the Growth of MCF-7 Breast Cancer Cells
- 1 January 1998
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Molecular Pharmacology
- Vol. 53 (1), 62-76
- https://doi.org/10.1124/mol.53.1.62
Abstract
Originally purified as a major lipid component of a strain of the cyanobacterium Lyngbya majuscula isolated in Curaçao, curacin A is a potent inhibitor of cell growth and mitosis, binding rapidly and tightly at the colchicine site of tubulin. Because its molecular structure differs so greatly from that of colchicine and other colchicine site inhibitors, we prepared a series of curacin A analogs to determine the important structural features of the molecule. These modifications include reduction andE-to-Z transitions of the olefinic bonds in the 14-carbon side chain of the molecule; disruption of and configurational changes in the cyclopropyl moiety; disruption, oxidation, and configurational reversal in the thiazoline moiety; configurational reversal and substituent modifications at C13; and demethylation at C10. Inhibitory effects on tubulin assembly, the binding of colchicine to tubulin, and the growth of MCF-7 human breast carcinoma cells were examined. The most important portions of curacin A required for its interaction with tubulin seem to be the thiazoline ring and the side chain at least through C4, the portion of the side chain including the C9–10 olefinic bond, and the C10 methyl group. Only two modifications totally eliminated the tubulin-drug interaction. The inactive compounds were a segment containing most of the side chain, including its two substituents, and analogs in which the methyl group at the C13 oxygen atom was replaced by a benzoate residue. Antiproliferative activity comparable with that observed with curacin A was only reproduced in compounds that were potent inhibitors of the binding of colchicine to tubulin. Molecular modeling and quantitative structure-activity relationship studies demonstrated that most active analogs overlapped extensively with curacin A but failed to provide an explanation for the apparent structural analogy between curacin A and colchicine.This publication has 30 references indexed in Scilit:
- Absolute Configuration and Total Synthesis of (+)-Curacin A, an Antiproliferative Agent from the Cyanobacterium Lyngbya majusculaJournal of the American Chemical Society, 1997
- Total Synthesis of the Antimitotic Marine Natural Product (+)-Curacin AThe Journal of Organic Chemistry, 1996
- Curacins B and C, New Antimitotic Natural Products from the Marine Cyanobacterium Lyngbya majusculaJournal of Natural Products, 1995
- Synthesis of Curacin A: A Powerful Antimitotic from the Cyanobacterium Lyngbya majusculaJournal of the American Chemical Society, 1995
- Structure of Curacin A, a Novel Antimitotic, Antiproliferative and Brine Shrimp Toxic Natural Product from the Marine Cyanobacterium Lyngbya majusculaThe Journal of Organic Chemistry, 1994
- Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell LinesJNCI Journal of the National Cancer Institute, 1991
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI Journal of the National Cancer Institute, 1990
- The role of the B-ring of colchicine in the stability of the colchicine-tubulin complexBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1987
- Stabilization of the colchicine-binding activity of tubulin by organic acidsBiochimica et Biophysica Acta (BBA) - General Subjects, 1981
- An optimized conjugate gradient solution for least-squares equationsActa Crystallographica Section A, 1978